Chronic lymphocytic leukaemia (CLL) consists of two biologically and clinically distinct subtypes defined by the abundance of somatic hypermutation (SHM) affecting the Ig variable heavy-chain locus (IgHV). The molecular mechanisms underlying these subtypes are incompletely understood. Here, we present a comprehensive whole-genome sequencing analysis of somatically acquired genetic events from 46 CLL patients, including a systematic comparison of coding and non-coding single-nucleotide variants, copy number variants and structural variants, regions of kataegis and mutation signatures between IgHV mut and IgHV unmut subtypes. We demonstrate that one-quarter of non-coding mutations in regions of kataegis outside the Ig loci are located in genes relevant to CLL. We show that non-coding mutations in ATM may negatively impact on ATM expression and find non-coding and regulatory region mutations in TCL1A, and in IgHV unmut CLL in IKZF3, SAMHD1, PAX5 and BIRC3. Finally, we show that IgHV unmut CLL is dominated by coding mutations in driver genes and an aging signature, whereas IgHV mut CLL has a high incidence of promoter and enhancer mutations caused by aberrant activation-induced cytidine deaminase activity. Taken together, our data support the hypothesis that differences in clinical outcome and biological characteristics between the two subgroups might reflect differences in mutation distribution, incidence and distinct underlying mutagenic mechanisms.
INTRODUCTION
Chronic lymphocytic leukaemia (CLL) is the most common form of adult leukaemia in the Western world, 1 accounting for one-third of new cases of leukaemia each year. 2 CLL is characterised by significant clinical heterogeneity. While one-third of patients never require any treatment, others invariably progress and ultimately develop chemorefractoriness. This clinical heterogeneity is reflected at least in part by characteristic biological features. Chromosomal deletions and amplifications are among the most common genomic aberrations described in CLL 3 and have been associated with diverse phenotypes and contrasting clinical behaviour. 4 Genome 5, 6 and exome-wide 7 sequencing efforts have identified a number of recurrent acquired mutations in the coding regions of genes. Mutations in the coding regions of TP53, [8] [9] [10] SF3B1, 7, 11, 12 NOTCH1, 13-15 RPS15 16 and SAMHD1 17 have been associated with chemorefractoriness, advanced disease, poor prognosis and/or transformation to high-grade lymphoma.
A recent study, using a combination of whole-genome sequencing (WGS) and whole-exome sequencing, addressed for the first time the potential significance of non-coding mutations in CLL 18 and, in doing so, characterised a region of kataegis affecting an enhancer site 300 kb upstream of the PAX5 gene. Kataegis is characterised by hotspots of somatically acquired mutations that are scattered throughout the genome. The study also described splice-site mutations in NOTCH1, which have since been correlated with clinical outcome. 19 The study illustrates the potential of WGS to reveal important driver mutations outside the protein-coding regions.
During B-cell development, somatic point mutations are introduced at the Ig variable gene loci via the action of activation-induced cytidine deaminase (AID). CLL is divided into two distinct subgroups: those with little or no somatic hypermutation (SHM) and unmutated Ig variable heavy-chain locus (IgHV unmut ), defined by ⩾ 98% homology to the germline IgHV sequence, and those with IgHV hypermutated CLL (IgHV mut ) (o 98% germline homology). IgHV mut patients have significantly better treatment-free and overall survival than IgHV unmut patients. 20 Importantly, there is accumulating evidence that at least a proportion of IgHV mut patients might achieve cure following chemoimmunotherapy. 21, 22 Using targeted deep sequencing of the IgHV locus, our group recently demonstrated that 25% of CLL carry additional small IgHV subclones that further refine the prognostic value of the IgHV status. 23 IgHV unmut and IgHV mut CLL also differ in their gene expression 24, 25 and genomewide methylation profiles. 26 These differences in transcriptional output and clinical behaviour might be due to differences in B-cell receptor signalling response to antigens. 27 Alternatively, cellautonomous and antigen-independent signalling could be a crucial pathogenic mechanism in both types of CLL, independent of IgHV status. 28 Recent WGS studies have identified various mutation signatures in CLL, 29, 30 including AID-and aging-related signatures, and there is evidence for the full range of AID activity in both IgHV unmut and IgHV mut CLL. 31 We therefore hypothesised that the clinical and biological differences seen might be due to differences in the activity and target loci of AID and/or other mutagenic mechanisms between these two groups. One previous study examined mutation signatures in good-risk CLL with isolated deletion of 13q and IgHV mut . 32 Here, we therefore included patients with IgHV unmut poor-risk CLL and compared the coding and noncoding mutation spectrum between the two groups. To perform a more rigorous analysis of the non-coding space, we used experimentally determined CLL-specific chromatin immunoprecipitation followed by high-throughput sequencing (ChIP-seq) and assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq) data in combination with existing data from the ENCODE project 33,34 to produce bespoke non-coding annotations. We then developed an in silico annotation pipeline for these mutations that included the identification of regions of kataegis, and revealed distinct patterns in the occurrence and distribution of mutations between IgHV unmut and IgHV mut subgroups. From our experimental data, we also identify noncoding and mutations in regulatory elements of known cancerrelated genes that we link to IgHV unmut CLL. Finally, we show the potential association of these non-coding mutations with gene expression using paired RNA-seq data from the same patients. Taken together, our data support the hypothesis that the difference in clinical outcomes observed between IgHV unmut and IgHV mut is due, at least in part, to differences in the genomic footprint between these two subgroups. Further, it reveals known cancer-linked genes frequently mutated in the IgHV unmut subtype that may be candidates for a deeper understanding of these differences.
PATIENTS AND METHODS

Patient and sample characteristics
We isolated tumour and germline DNA from peripheral blood and saliva samples, respectively, of 46 CLL patients diagnosed at the Oxford University Hospitals, Oxford, or the Karolinska Institute, Stockholm. Informed consent was obtained in line with the Declaration of Helsinki and local research ethics committees. The median age was 69 (range 49-94) years. Fifty-nine per cent (27/46) were male. Sixteen cases were IgHV mut and 27 were IgHV unmut . Patients with the IgHV 3-21 rearrangement have been shown to display the same poor prognostic indications as those with unmutated Ig genes. 35 Thus, three cases with o98% homology to the Ig germline sequence, harbouring the V3-21 rearrangement, were also classified as IgHV unmut . Of the 16 IgHV mut patients, 5 were refractory and 11 naïve, and of the 30 IgHV unmut samples, 17 were refractory and 13 naïve. We also subjected 31 samples to targeted deep sequencing of the IgHV gene as described previously. 23 Eight patients had been treated with at least one round of chemotherapy before WGS ( Supplementary  Figures 5 and 6 ). Twenty-two cases developed chemorefractoriness subsequent to sequencing, defined by either relapse ⩽ 24 months following initial treatment or the presence of TP53 disruption. Twentytwo were chemosensitive, while the status of the remaining two was unknown (Supplementary Table 1 ).
WGS and annotation
Matched tumour and germline WGS libraries were prepared from 2 μg DNA using the TruSeq DNA PCR Free Library Preparation Kit (Illumina, San Diego, CA, USA). Libraries were subjected to 2 × 35 bp paired-end sequencing on a HiSeq 2500 instrument (Illumina), to a mean sequencing depth of 39x for tumour (range [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] and 36x for germline (range samples. Alignment of sequencing reads to the hg19 human genome build was performed using iSAAC v.01.13.04.04. 36 SNVs and indels were called using Starling v.2.0.3 and Strelka v.2.0.10. 37 Germline mutations were subtracted from the matched tumour and filtered and annotated using our in-house pipeline (Supplementary Methods).
Experimentally determined CLL-specific epigenetics data was generated in the context of the Blueprint Project by ATAC-seq and ChIP-seq on six histone modification marks with non-overlapping functions (H3K4me3, H3k27ac, H3K4me1, H3K27me3, H3K36me3 and H3K9me3). Both methods were performed according to standard protocols available through the Blueprint Portal (http://www.blueprint-epigenome.eu/index.cfm?p = 7BF8A4B6-F4FE-861A-2AD57A08D63D0B58). Chromatin states were identified using the chromHMM Software, 38 
Whole transcriptome sequencing
Whole transcriptome sequencing libraries were prepared using the TruSeq Stranded Total RNA Sample Preparation Kit (Illumina). Libraries underwent 2 × 76 bp paired-end sequencing on a HiSeq 2500 instrument (Illumina). Sequence data was aligned to the hg19 build of the human genome using TopHat. 39 
Data analysis
Copy number alterations (CNAs) and structural rearrangements were identified using Nexus (Biodiscovery Inc., El Segundo, CA, USA) and DELLY, 40 respectively. Regions of kataegis within individual patients were identified using methods described previously. 41 A further in-house pipeline was used to identify regions of higher mutational load across the cohort (Supplementary Methods). The presence of mutational signatures were determined using methods described previously. 42, 43 (Supplementary Methods).
Statistical analysis
Statistical analyses were performed using SPSS version 22 (IBM, Armonk, NY, USA) and Prism version 5 (GraphPad, La Jolla, CA, USA). Categorical variables were compared using either the χ 2 test or Fisher's exact test as appropriate. Survival analysis was performed using the Kaplan-Meier method. P-values were considered significant at the 0.05 level.
RESULTS
Somatic mutation distribution and density
After imposing a rigorous QC step, the number of bona fide mutations per tumour ranged from 516 to 2697 per sample (median, 1426) ( Figure 1a and Supplementary Table 2), corresponding to a mean mutation rate of 0.49 ± 0.16 per megabase (range 0.17-0.9). Of these, 823 missense, 62 nonsense and 85 splice-site mutations occurred in protein-coding regions. Of the 3260 insertion/deletions detected across the genomes, 62 affected protein-coding regions. While the overall mutation rate outside the Ig loci was higher in IgHV mut tumours compared with that in IgHV unmut samples (P = 0 0089, unpaired t-test; Figure 1b) , there was no difference across all coding regions (P = 0.1191, unpaired t-test). IgHV unmut cases did, however, show an enrichment for coding mutations in the known CLL driver genes 16, 44 (P = 0.0380, unpaired t-test; Figure 1c ), consistent with a more aggressive phenotype. Furthermore, upon examining the genomic context of the mutations, we discovered significant enrichment for variants within gene promoter regions in IgHV mut patients (P o0.0001, unpaired t-test; Figures 1d and e) . 45 (70-90.5 Mb) was seen in three tumours, but was not associated with differential expression of REL, ALK or MYCN, which mapped to the minimally deleted region. Del(8p) was also seen in three patients (CLL364, CLL154 and CLL372). It was noteworthy that del(8q) was associated with other CNAs-del (11q), gain (12) and del(17p) (CLL364), del(11q) and del(17p) (CLL372) and del(13q) (CLL154). This concurs with other studies, which have reported that del8p deletions often coexist with other CNAs. 46, 47 Tumour CLL364 was also the only one to display chromothripsis.
Structural variants
We detected 79 interchromosomal translocations in the tumours from 30 of the 46 patients (average of 1.7 per case, range 1-9; Figure 2 and Supplementary Table 4 ). Seventeen of the 79 events (22%) were predicted to generate gene fusion proteins (tier 1). Two IgHV mut cases (CLL301 and CLL348) had IGH/BCL2 t(14;18) fusions, and a single IgHV unmut case had IGH/BCL3 t(14;19). RNAseq data was available in 22 out of the 30 patients (73%, 22/30).
The other interchromosomal translocations involved either the coding region of a gene (tier 2, 44%, 35/79) or intergenic regions (tier 3, 34%, 27/79). RNA expression supported the functional consequences of t(14;18) (IGH/BCL2), t(2;9) (DPP10;SET) and both Figure 1) . Somatic mutation profiles Coding mutations. As expected, somatic mutations in the coding regions of SF3B1, TP53, ATM and NOTCH1 were the most frequent, occurring in 30.4% (14/46), 19.6% (9/46), 15.2% (7/46) and 13% (6/46) of patients, respectively. The missense Lys700Glu substitution in SF3B1 (28%, 4/14), between the third and fifth HEAT domains, affected mainly IgHV unmut patients, although this did not reach significance (P = 0.316). Missense mutations were also the most frequent type found in TP53 (82%, 9/11), occurring in the DNA-binding domain and in all previously described in the COSMIC database. Two cases harboured indels within TP53, one 4 bp deletion in exon 4 and one 19 bp deletion in exon 5. Again, TP53 mutations were more common in IgHV unmut patients (9/11, 82%), but not to a significant level (P = 0.463). Seven cases contained eight mutations within the coding region of ATM, comprising six missense mutations, a 5 bp deletion in exon 53 and one stop gain mutation in exon 25, resulting in the loss of 60% of the coding sequence. Mutations in NOTCH1 were confined to exon 34, with 71% (5/7) comprising the c.7541_7542delCT variant resulting in early termination of the PEST domain. In addition, we identified a number of low-frequency recurrent mutations. The tumour suppressor gene FAT1 harboured protein-coding mutations in 11% of samples (5/46), encompassing both chemorefractory and untreated cases. 48 Most mutations in FAT1 occurred within exon 2 (60%, 3/5), including a nonsense mutation at residue Lys125, resulting in the loss of 497% of the coding region. We detected five missense and two synonymous mutations in KLHL6 across two patients. In one case, three mutations (Arg66Gly, Met67Thr and Val88Glu) were clustered close together in exon 1, and both cases were IgHV mut as described previously. 5 Other previously described candidate driver genes harboured low-frequency variants, including two mutations each in MYD88, SAMHD1, DDX3X and BIRC3, with one each in FBXW7, XPO1, CHD2 and POT1. 5, 6, 12, 14, 17, 44 Mutations in non-coding and regulatory regions. Localised regions of increased mutation density, also referred to as kataegis, have been described previously in other types of cancer. Here, we used both previously described methods 41 and our own approaches to identify these regions in our cohort (Supplementary Methods).
To this end, we first examined each CLL genome individually, where we detected 74 kataegic regions across 31 samples affecting 14 chromosomes. Some chromosomal regions were recurrently affected, most notably, and as expected, those encoding the Ig light and heavy chains on chromosomes 2 (11/74, 15%), 14 (33/74, 45%) and 22 (13/74, 18%). These regions accounted for 88% (1397/1591) of all kataegic mutations. IgHV mut cases harboured significantly more kataegic regions than IgHV unmut cases (P = 0.0004), a relationship that continued even after removing regions found at the Ig loci (P = 0.0308). The 19 non-Ig regions occurred in 11 patients and ranged in length from 219 bp to 159 kbp. Fourteen were located within or across gene boundaries. Importantly, almost half of these (6/14, 43%) affected non-coding regions of genes were known to also carry coding mutations in CLL including KLHL6, (Table 1 and Supplementary Table 5 ). In one IgHV mut case, CLL144, a kataegic region was identified within ATM, comprising 10 mutations in a 9 kb span between exon 10 and intron 16. Eighty per cent (8/10) of the mutations occurred in intronic regions, with two more in exon 10. The two coding mutations affected adjacent bases, but resulted in a single serine to valine residue substitution (Ser478Val), predicted as tolerated by the sorting tolerant from intolerant algorithm. Experimentally determined ChIP-seq data revealed that all 10 mutations occurred in regions of strong H3K36 trimethylation, which is an indication of transcription elongation. 38 Analysis of paired RNA-seq data from CLL144 revealed a similarly reduced level of ATM expression as seen in cases harbouring del(11q). Furthermore, cases with del (11q) showed significantly lower ATM expression levels than ATM wild-type cases (P = 0.0016), as expected 50 ( Figure 3 ). Sites of kataegis have been shown to colocalise with structural rearrangements. 42, 52 As such, the 19 kataegic regions that were Five were found to be in close proximity to structural alteration events (Supplementary Table 6 ). In line with previous observations, 42, 52 this suggests that kataegis can indicate the presence of structural rearrangements.
Second, we combined the WGS data from all 46 CLL samples, and used a combination of methods to highlight strict regions of kataegis, alongside wider mutational hotspots (Supplementary Methods). Through this approach, we identified 159 additional kataegic regions, which were further annotated for the presence of coding and non-coding regulatory regions using a combination of functional data obtained from normal B cells, CLL cell lines and primary CLL. Sites were defined as active regulatory regions if they fell within chromatin states containing H3K27 acetylation (that is, active promoters, strong enhancers or transcription transition), as determined using the CLL-specific ChIP-seq data (see Supplementary Methods). With the exception of the 9q34.3 locus of NOTCH1, 51 regions were excluded from further analysis because of their centromeric or telomeric location. In addition to the expected clustering of coding mutations in SF3B1, TP53, NOTCH1 and KLHL6, occurring predominantly in IgHV unmut patients, the remaining 108 regions included 21 clusters of noncoding mutations lying in active regulatory promoter or enhancer regions of genes expressed in CLL cells. The majority of these regions occurred in either the Ig loci (52%, 11/21) or within regulatory regions of known targets of SHM, including BCL6, TCL1A, BTG2 and BACH2, 53, 54 and were more common in IgHV mut patients ( Figure 4 ). We were unable to find previously described mutations in the splice-site region of NOTCH1. 18 This is likely due to their low incidence of~2%. 18 Third, we performed a further hotspot analysis to identify recurrently mutated regions and genes with fewer variants than are required to be classified as kataegis. This revealed IKZF3 mutations in three IgHV unmut patients and a further five with mutations in regulatory regions, only one of which was IgHV mut . We also detected SAMHD1 coding mutations in two IgHV unmut cases and three mutations in active regulatory elements in two IgHV unmut and one IgHV mut case (Figures 4a and b and Supplementary Figures 2 and 3) . Both IKZF3 and SAMHD1 have been identified as driver genes in CLL. 16, 17, 44 Furthermore, we identified clusters of mutations within active enhancer and promoter regions of ST6GAL1 in nine IgHV mut patients and three IgHV unmut patients. Overexpression of ST6GAL1 has been linked to chemoresistance in leukaemia 55 and indeed two of the affected cases were confirmed chemorefractory with otherwise good-risk features. Mutations affecting the PAX5 enhancer region have been recently described in CLL, 18, 56 and, indeed, in our cohort a single IgHV mut patient, CLL351, harboured a mutation in this region. Additionally, we identified eight mutations within the boundaries of the PAX5 gene, and which correlated with non-coding elements, in our cohort, comprising seven mutations across six IgHV unmut patients and one mutation in one IgHV mut patient. Six of these mutations were located in sites of transcription elongation, and the remaining two in promoter and enhancer regions (Supplementary Figure 4) .
Finally, we focussed on the regulatory regions of genes with strong a priori relevance to CLL biology. This analysis was restricted to sites at active regulatory regions (Supplementary Methods) in genes expressed in CLL cells. Here, only instances that harboured mutations in at least two patients in a given region were counted. This analysis revealed a number of recurrently Genomic footprint of IgHV mut and IgHV unmut CLL A Burns et al mutated active regulatory regions in genes involved in key pathways including B-cell development (BCL6, IKZF1, PAX5), nuclear factor-κB signalling (TCL1A, BACH2, BIRC3, VOPP1), NOTCH signalling (HDAC9) and DNA damage response (BTG2, BCL2) ( Figure 5 ). With the exception of a subset of BCL-2 promoter mutations that were linked to t(14;18) in two of three patients, paired RNA-seq data from the same patients did not reveal any differences in gene expression compared with patients without mutations in these regions (data not shown). As it can be difficult to uncouple treatment effect with biological effect, an association plot was constructed dividing data by chemoresistance and specifying previously treated patients (Supplementary Figures 5  and 6) ; however, no clustering was found within these groups.
Mutation signatures. Finally, we asked whether the difference in mutation distribution could arise as a consequence of the action of distinct mutagenic mechanisms. By using complex mathematical modelling, it has become possible to isolate a number of mutational patterns, or signatures, within the molecular landscape of cancer. 29, 30, 42, 57 Although previously derived mutation signatures are extensive, they focus solely on exome data, and not whole genomes. Here, our aim was to compare the age, AID content and apolipoprotein B mRNA editing enzyme catalytic polypeptide (APOBEC) content of our samples with the mutational signatures found in our complete data. Thus, for our initial analysis we derived novel mutation signatures. We used our WGS data to extract three distinct mutational signatures from our cohort. Tumour signature 1 (Tsig1) is dominated by C4T transitions in NpCpG and NpCpC contexts accounting for 56.8 and 5.5% of the signature, respectively (Figure 6a ). Tumour signature 2 (Tsig2) is again defined primarily by C4T transitions in NpCpG trinucleotides; however, the occurrence of T4G transversions and T4C transitions at NpTpN sites differentiates it from Tsig1 (Figure 6a ). Tsig3 is characterised by substitutions involving cytosine residues, with C4T, C4A and C4G variants at NpCpG trinucleotides accounting for 63% of the signature.
Previously, three mutational signatures were described in CLL, 29 attributed to the ageing process, and the ongoing presence of AID and APOBEC activity. To examine the relationship between these factors and the signatures in our data, we used a generalised linear model to correlate the proportion of each signature present in each sample with the levels of APOBEC and AID mutations, and the age of the patient (Figure 6b ). We identified a strong positive correlation between Tsig1 and APOBEC mutations and a correlation between Tsig2 and the noncanonical AID signature. We also examined our data for the presence of any of the 21 Alexandrov signatures, of which we identified 5 (1b, 5, 8, 9 and 16) (Figure 6c ). Signature 1b is generally attributed to ageing, and showed a strong correlation with our Tsig1. However, in our cohort, neither signature 1b nor Tsig1 correlated with the age of the patient. Instead, we saw a significant increase in the proportion of Tsig1 in the refractory and IgHV unmut patient groups. Owing to the overlap between these groups in our cohort, it was impossible to ascertain whether this correlation was independent. However, it strongly suggests that the underlying mechanism for the increase in Tsig1 in these patients might be exposure to previous chemotherapy and/or genomic instability. Tsig2-matched signature 9 is attributed to noncanonical AID activity and Ig hypermutation. As expected, both signature 9 and Tsig2 in our cohort are present at significantly higher levels in the IgHV-mutated cohort (Figure 6c ). In summary, we were able to identify statistically significant differences in the proportion of mutation signatures between IgHV unmut and IgHV mut for Sig1b and Tsig1, Sig8, Sig9 and Tsig2, and Sig16.
DISCUSSION
Here we have used WGS to provide a comprehensive genomewide description of the landscape of non-coding mutations of both IgHV mut and IgHV unmut CLL. We reveal significant differences in the distribution of both somatic mutations and mutation signatures between these two subgroups. Previous WGS studies of CLL have focussed on good-risk treatment-naïve patient groups, such as those with monoclonal B-cell lymphocytosis or early stage CLL 18 or IgHV mut CLL with concurrent del(13q). 56 Here we have extended these published data sets and were able to compare it with the WGS data from poor-risk patients, many of whom were either IgHV unmut and/or refractory to chemoimmunotherapy. First, this genome-wide comparison of the mutation distribution between IgHV mut and IgHV unmut patients revealed a distinctive pattern for each subtype, with exonic CLL driver gene mutations being more common in IgHV unmut patients, whereas mutations in regulatory elements of B-cell master regulators were more frequently observed in IgHV mut patients. We developed and implemented a highly stringent filtering pipeline that excluded a large proportion of the genome, including repetitive, centromeric and telomeric domains to reduce the number of false-positive variants. Importantly, we only included mutations in DNAse hypersensitivity sites or in regions of H3K4me3, H3K9ac, H3K4me1 or H3K27ac marks and complemented these with RNA-seq, and experimental CLL-specific data derived from ChIP-seq and ATAC-seq (see Supplementary Methods). Annotations were assigned to the 'active non-coding element' classes of active promoter, strong enhancer or transcription transition sites from these primary CLL cells using chromHMM. This analysis revealed that at least 50% of somatically acquired mutation hotspots in regulatory regions of individual patients are located in genes found to also carry mutations in coding regions in CLL. In the case of non-coding mutations in ATM, these appeared to associate with altered RNA expression levels of these genes.
By performing a cohort-wide kataegis analysis, we were able to corroborate the findings of other groups with regard to the presence of mutations affecting the enhancer region of PAX5 in IgHV mut patients. 18, 56 Transcription elongation (H3K36me3) and active promoter mutations were seen in PAX5 in 6/27 (22%) of IgHV unmut patients (Supplementary Figure 4) . H3K36 trimethylation has been noted in yeast as a mechanism for the deacetylation of coding regions, thus stopping overactive transcription, 58 and there is some evidence to suggest that it might have a similar role in humans. 59 However, no effect on gene expression was found in our data (data not shown). We also found that 6 of 46 (13%) patients carried at least one mutation in the promoter region of TCL1A (Supplementary Figure 7) . TCL1A is a direct activator of nuclear factor-κB. Translocations leading to TCL1A overexpression (t(14;14)(q11; q32)) by putting TCL1A expression under the control of the IgHV promoter have been described as rare events in lymphomas. Besides, the TCL1A promoter has previously been shown to display hypomethylation in CLL cells, providing an alternative mechanism for TCL1A upregulation in CLL. 60, 61 Moreover, microRNA dysregulation has also been proposed as a cause for TCL1A overexpression. 62 In our series of patients, there was no difference in the TCL1A RNA expression in patients with or without mutations in the TCL1A promoter.
Importantly, we describe for the first time a number of somatically acquired genomic events that occurred predominantly or exclusively in patients in IgHV unmut patients: (1) We identified for the first time coding and non-coding mutations in IKZF3 in almost 30% of IgHV unmut patients (8 mutations in 8/27 patients), making IKZF3 one of the most frequently mutated genes in high-risk CLL (Figure 4a ). IKZF3 is known to be overexpressed in CLL, and epigenetic modification of its promoter region has previously been described as one of the underlying mechanisms. 63 In the same study, overexpression or downregulation of IKZF3 was shown to affect the expression of some Bcl-2 family members including BCL-2, thereby regulating apoptosis and cell survival. We can speculate that direct mutations in promoter and/or enhancer regions of IKZF3 might represent either an alternative or complementary mechanism driving IKZF3 deregulation in CLL. Further functional work will be required to understand their precise impact on CLL biology. In addition, mutations in the IKZF3 paralogue IKZF1 were found in active promoter regions in two IgHV unmut patients (Supplementary Figure 8) . Similar to IKZF3, IKZF1 is a regulator of lymphocyte differentiation and has been linked to childhood B-cell precursor acute lymphoblastic leukaemia. 64 (2) Coding mutations in SAMHD1 occurred in two IgHV unmut patients, with three mutations in active regulatory regions in another three patients (Figure 4b ). Somatically acquired germline mutations in the SAMHD1 coding region have been shown to exist as founder events, regulating cell proliferation and survival, in relapsed and refractory CLL patients. 17, 44 (3) BIRC3 mutations in an active promoter or transcription elongation site occurred in 4/27 IgHV unmut patients and one IgHV mut patient (Figure 4c ). BIRC3 is a known cancer driver gene involved in nuclear factor-κB signalling. Exonic SNV mutations and deletions have been described previously and are associated with poor-risk disease. 65 (4) In all cases of regulatory mutations, further experimental analyses are required to fully link mutations to altered gene expression.
(5) Finally, we identify differences in the distribution of a number of mutation signatures, in particular the AID and aging signatures, pinpointing different pathogenic mechanisms of leukemogenesis. First, although the AID signature is more abundant in IgHV mut CLL, it is also prevalent in IgHV unmut CLL. These data are consistent with recent studies, which found that AID expression and full functional activity are intact in both IgHV mut and IgHV unmut CLL, 31 and that canonical AID activity is an ongoing process in IgHV mut patients. 32 Conversely, IgHV unmut and chemoimmunotherapy refractory CLL are dominated by the aging signature. This was independent of the age of the patient and implies that the increased incidence of driver mutations in this subgroup might be caused by repeated cell divisions, genomic instability and prior exposure to DNA-damaging agents rather than aberrant AID activity.
In conclusion, we provide evidence that in addition to recurrent mutations in the coding elements of the genome, non-coding mutations in known regulatory regions of critical B-cell transcription factors such as PAX5 or IKZF3 occur in significant subsets of CLL. On the basis of their mutation frequency in regulatory regions in several patients with IgHV unmut CLL, we propose a number of genes including IKZF3, BIRC3 and SAMHD1 as warranting further functional investigation into the differences between IgHV mut and IgHV unmut CLL. Finally, we identify for the first time different dominant mutagenic mechanisms between these different types of CLL. The identification of the differences in the distribution of non-coding mutations between IgHV mut and IgHV unmut CLL is the first step towards an in-depth functional analysis. However, the fact that certain non-coding regions are recurrently targeted by mutations in a significant number of patients and that the majority of these occur in genes also targeted by mutations in the exome is in itself evidence for their functional relevance in CLL pathogenesis. Our data therefore supports the hypothesis that the biological and clinical differences observed between IgHV unmut and IgHV mut CLL are due, at least in part, to differences in the genomic footprint between these two subgroups and that regulatory mutations present a crucial avenue for further investigation.
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